Journal
CLINICAL SCIENCE
Volume 131, Issue 5, Pages 395-409Publisher
PORTLAND PRESS LTD
DOI: 10.1042/CS20160413
Keywords
-
Categories
Funding
- Ted Rogers Centre for Heart Research
- Canadian Institutes of Health Research
- FAMY, FAMY Norrbotten and Amyl
- Prothena Inc.
- Erik, Karin and Gosta Selander's Foundation
Ask authors/readers for more resources
Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is an underdiagnosed and important type of cardiomyopathy and/or polyneuropathy that requires increased awareness within the medical community. Raising awareness among clinicians about this type of neuropathy and lethal form of heart disease is critical for improving earlier diagnosis and the identification of patients for treatment. The following review summarizes current criteria used to diagnose both hereditary and wild-type ATTR (ATTRwt) amyloidosis, tools available to clinicians to improve diagnostic accuracy, available and newly developing therapeutics, as well as a brief biochemical and biophysical background of TTR amyloidogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available